DK3169405T3 - Fremgangsmåder, forbindelser og sammensætninger til behandling af muskel- og skeletsygdomme - Google Patents

Fremgangsmåder, forbindelser og sammensætninger til behandling af muskel- og skeletsygdomme Download PDF

Info

Publication number
DK3169405T3
DK3169405T3 DK15822317.2T DK15822317T DK3169405T3 DK 3169405 T3 DK3169405 T3 DK 3169405T3 DK 15822317 T DK15822317 T DK 15822317T DK 3169405 T3 DK3169405 T3 DK 3169405T3
Authority
DK
Denmark
Prior art keywords
compositions
compounds
treatment
methods
musculoskeletal diseases
Prior art date
Application number
DK15822317.2T
Other languages
English (en)
Inventor
Kathleen E Rodgers
Stan G Louie
Gere S Dizerega
Nicos A Petasis
Kevin J Gaffney
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Application granted granted Critical
Publication of DK3169405T3 publication Critical patent/DK3169405T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK15822317.2T 2014-07-17 2015-07-17 Fremgangsmåder, forbindelser og sammensætninger til behandling af muskel- og skeletsygdomme DK3169405T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462026006P 2014-07-17 2014-07-17
US201462053035P 2014-09-19 2014-09-19
PCT/US2015/041020 WO2016011420A1 (en) 2014-07-17 2015-07-17 Methods, compounds, and compositions for the treatment of musculoskeletal diseases

Publications (1)

Publication Number Publication Date
DK3169405T3 true DK3169405T3 (da) 2024-09-23

Family

ID=55079111

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15822317.2T DK3169405T3 (da) 2014-07-17 2015-07-17 Fremgangsmåder, forbindelser og sammensætninger til behandling af muskel- og skeletsygdomme

Country Status (10)

Country Link
US (1) US9943509B2 (da)
EP (1) EP3169405B1 (da)
JP (1) JP2017521390A (da)
KR (2) KR20170026368A (da)
CN (1) CN107073295A (da)
AU (1) AU2015289420B2 (da)
CA (1) CA2953064C (da)
DK (1) DK3169405T3 (da)
RU (1) RU2016152088A (da)
WO (1) WO2016011420A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201810837QA (en) 2016-06-29 2018-12-28 Univ Montreal Biarylmethyl heterocycles
US11446285B2 (en) 2017-06-16 2022-09-20 University Of Southern California Methods for treating systemic lupus erythematosus
WO2019027890A1 (en) * 2017-08-04 2019-02-07 Gaffney Kevin J METHODS OF TREATING MYELOSUPPRESSION
EP3946284A1 (en) * 2019-03-28 2022-02-09 Société des Produits Nestlé S.A. Novel depside dimeric compounds for skeletal muscle modulation, methods and uses thereof
KR20230156030A (ko) * 2021-01-28 2023-11-13 케퍼시티 바이오 인코포레이티드 질환 치료를 위해 미토콘드리아 전환을 자극하는 방법 및 제제
WO2022229351A1 (en) * 2021-04-28 2022-11-03 Graviton Bioscience Bv Selective inhibitors of rock2 for the treatment of muscular dystrophy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
YU78601A (sh) 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
DE10112041A1 (de) 2001-03-14 2002-09-26 Aventis Pharma Gmbh p-Thienylbenzyl-Amide als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
TWI406850B (zh) * 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
WO2011005674A1 (en) * 2009-07-07 2011-01-13 Theravance, Inc. Dual-acting pyrazole antihypertensive agents
US8481549B2 (en) 2010-01-19 2013-07-09 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
WO2013078261A1 (en) * 2011-11-22 2013-05-30 The University Of Maryland, Baltimore Treatment of muscular conditions and muscular dystrophies
BR132012028005E2 (pt) * 2012-10-31 2014-11-18 Univ Minas Gerais Composições farmacêuticas contendo um agonista do receptor mas para o tratamento de doenças degenerativas musculares.
EP3935944A1 (en) 2013-03-15 2022-01-12 University Of Southern California, USC Stevens Compounds for the treatment of musculoskeletal diseases
WO2014189634A1 (en) 2013-04-19 2014-11-27 University Of Iowa Research Foundation Angiotensins in muscular dystrophy

Also Published As

Publication number Publication date
EP3169405B1 (en) 2024-08-28
WO2016011420A1 (en) 2016-01-21
CA2953064A1 (en) 2016-01-21
US20170119748A1 (en) 2017-05-04
EP3169405A4 (en) 2018-01-24
CA2953064C (en) 2023-06-20
NZ727422A (en) 2023-12-22
EP3169405A1 (en) 2017-05-24
US9943509B2 (en) 2018-04-17
AU2015289420B2 (en) 2021-03-11
JP2017521390A (ja) 2017-08-03
RU2016152088A (ru) 2018-08-21
KR20170026368A (ko) 2017-03-08
AU2015289420A1 (en) 2017-01-12
KR20230020584A (ko) 2023-02-10
KR102697698B1 (ko) 2024-08-21
RU2016152088A3 (da) 2019-02-12
CN107073295A (zh) 2017-08-18

Similar Documents

Publication Publication Date Title
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3326641T3 (da) Rna-holdig sammensætning til behandling af tumorsygdomme
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3492632T3 (da) Metoder til behandling af lithiumholdige materialer
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3227262T3 (da) Sulfidalkyl og pyridyl-revers-sulfonamidforbindelser til hbv-behandling
DK3143025T3 (da) Forbindelser til behandling af spinal muskelatrofi
DK3594238T3 (da) Antistofsammensætninger til tumorbehandling
DK3377516T3 (da) Sammensætning til behandling af cancer
DK3851537T5 (da) Behandling af hyperbilirubinæmi
DK3092256T3 (da) Forbindelser og sammensætninger til immunterapi
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3204386T3 (da) Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3148529T3 (da) Forbindelser til behandling af hjernecancer
DK3524255T3 (da) Sammensætning til behandling af acne
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3209696T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
BR112016022976A2 (pt) Métodos para o tratamento de hcv
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation